Tesamorelin

What It Is

A synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the full 44-amino-acid GHRH sequence with a trans-3-hexenoic acid modification that improves stability.

How It Works

Tesamorelin binds to GHRH receptors on the pituitary

→

Pituitary releases endogenous growth hormone

→

GH stimulates lipolysis in visceral fat depots

→

Visceral adipose tissue is selectively reduced

What Researchers Study It For

Visceral fat reduction pathways

Growth hormone secretion dynamics

Lipid metabolism and triglyceride levels

Body composition and adipose distribution

Common Research Protocols

Tesamorelin is reconstituted from lyophilized powder and administered via subcutaneous injection. It is one of the few GH-releasing peptides that has undergone extensive clinical evaluation, including large-scale trials examining its effects on trunk fat. Research protocols typically involve daily administration over multi-week study periods.

Community Interest Areas

Tesamorelin draws significant research interest for its specificity toward visceral adipose tissue rather than subcutaneous fat. The research community has explored it extensively in body composition studies, particularly in contexts where visceral fat accumulation is a primary variable. Its mechanism of stimulating endogenous GH release, rather than introducing exogenous GH, is a key point of differentiation.

44 Amino Acids Full GHRH sequence with stabilizing modification

Peer-Reviewed Evaluated in large-scale clinical trials for visceral adipose reduction

For research purposes only. Not intended for consumption, clinical application, or diagnostic use.

What It Is

How It Works

What Researchers Study It For

Common Research Protocols

Community Interest Areas

What Are Peptides?

Are Peptides Safe?